Panbela Therapeutics Inc (PBLA)

Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company listed on OTC Markets under the ticker PBLA. The company focuses on developing therapies for patients with serious medical conditions that have limited treatment options. Its pipeline includes Ivospemin (SBP-101), a proprietary polyamine analogue that has completed a Phase Ia/Ib trial in metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine and sulindac that is in Phase III clinical testing; and eflornithine, which is being evaluated in a Phase I/II trial as an enzyme-activated irreversible inhibitor of ornithine decarboxylase. Panbela also has a research agreement with the Johns Hopkins University School of Medicine related to ivospemin development. The company was previously known as Sun BioPharma, Inc. and adopted its current name in December 2020. Founded in 2011, Panbela is based in Waconia, Minnesota.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.